SG11202111120VA - Compounds against cancer bearing tyrosine kinase inhibitor resistant egfr mutations - Google Patents

Compounds against cancer bearing tyrosine kinase inhibitor resistant egfr mutations

Info

Publication number
SG11202111120VA
SG11202111120VA SG11202111120VA SG11202111120VA SG11202111120VA SG 11202111120V A SG11202111120V A SG 11202111120VA SG 11202111120V A SG11202111120V A SG 11202111120VA SG 11202111120V A SG11202111120V A SG 11202111120VA SG 11202111120V A SG11202111120V A SG 11202111120VA
Authority
SG
Singapore
Prior art keywords
tyrosine kinase
kinase inhibitor
against cancer
compounds against
egfr mutations
Prior art date
Application number
SG11202111120VA
Other languages
English (en)
Inventor
Jacqulyne Robichaux
Monique Nilsson
John Heymach
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of SG11202111120VA publication Critical patent/SG11202111120VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SG11202111120VA 2019-04-17 2020-04-16 Compounds against cancer bearing tyrosine kinase inhibitor resistant egfr mutations SG11202111120VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962835343P 2019-04-17 2019-04-17
PCT/US2020/028540 WO2020214824A1 (en) 2019-04-17 2020-04-16 Compounds against cancer bearing tyrosine kinase inhibitor resistant egfr mutations

Publications (1)

Publication Number Publication Date
SG11202111120VA true SG11202111120VA (en) 2021-11-29

Family

ID=72837936

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202111120VA SG11202111120VA (en) 2019-04-17 2020-04-16 Compounds against cancer bearing tyrosine kinase inhibitor resistant egfr mutations

Country Status (13)

Country Link
US (1) US20220175779A1 (enExample)
EP (1) EP3956035A4 (enExample)
JP (1) JP7709384B2 (enExample)
KR (1) KR20220004089A (enExample)
CN (1) CN113993592A (enExample)
AU (1) AU2020257395A1 (enExample)
BR (1) BR112021020601A2 (enExample)
CA (1) CA3132819A1 (enExample)
IL (1) IL287115A (enExample)
MX (1) MX2021012705A (enExample)
PH (1) PH12021552579A1 (enExample)
SG (1) SG11202111120VA (enExample)
WO (1) WO2020214824A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021010265A (es) 2019-02-26 2021-09-23 Janssen Biotech Inc Terapias de combinacion y estratificacion de pacientes con anticuerpos anti-egfr/c-met biespecificos.
US12629375B2 (en) 2019-03-29 2026-05-19 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing HER2 exon 21 insertions
MY208668A (en) 2019-05-14 2025-05-23 Janssen Biotech Inc Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
BR112022015140A2 (pt) 2020-02-12 2022-10-11 Janssen Biotech Inc Tratamento de pacientes que têm mutações de salto do éxon 14 de c-met
EP4284950A4 (en) * 2021-01-29 2024-12-25 Board of Regents, The University of Texas System METHODS OF TREATMENT OF CANCER USING KINASE INHIBITORS
US20240108623A1 (en) * 2021-01-29 2024-04-04 Board Of Regents, The University Of Texas System Methods of treating cancer with poziotinib
WO2023129667A1 (en) 2021-12-30 2023-07-06 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of flt3
CN115998743B (zh) * 2023-01-16 2024-05-28 威尚（上海）生物医药有限公司 喹唑啉类化合物在克服奥希替尼耐药中的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3120851A1 (en) * 2015-07-21 2017-01-25 Pangaea Biotech S.L. 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers
EP3458064A1 (en) * 2016-05-18 2019-03-27 Boehringer Ingelheim International GmbH Anticancer combination therapy
BR112019010020A2 (pt) * 2016-11-17 2019-08-20 Univ Texas compostos com atividade anti-tumoral contra células cancerosas contendo mutações de egfr ou her2 exon 20
WO2018213770A1 (en) * 2017-05-19 2018-11-22 Regents Of The University Of Minnesota Therapeutic methods
JP7386174B2 (ja) * 2018-03-27 2023-11-24 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｈｅｒ２エクソン１９変異を有するがん細胞に対する抗腫瘍活性を有する化合物
SG11202012064PA (en) * 2018-06-25 2021-01-28 Spectrum Pharmaceuticals Inc Combination of poziotinib with cytotoxic agent and/or other molecularly targeted agent and use thereof
KR20210066819A (ko) * 2018-09-04 2021-06-07 레인 세러퓨틱스 인코포레이티드 Her-유도 암을 치료 또는 예방하기 위한 화합물, 조성물 및 방법
MX2021010265A (es) * 2019-02-26 2021-09-23 Janssen Biotech Inc Terapias de combinacion y estratificacion de pacientes con anticuerpos anti-egfr/c-met biespecificos.
US20220143023A1 (en) * 2019-03-29 2022-05-12 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 insertions
US12629375B2 (en) * 2019-03-29 2026-05-19 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing HER2 exon 21 insertions

Also Published As

Publication number Publication date
MX2021012705A (es) 2021-11-12
CN113993592A (zh) 2022-01-28
JP2022529945A (ja) 2022-06-27
BR112021020601A2 (pt) 2021-12-07
AU2020257395A1 (en) 2021-11-04
WO2020214824A1 (en) 2020-10-22
PH12021552579A1 (en) 2022-08-01
CA3132819A1 (en) 2020-10-22
IL287115A (en) 2021-12-01
EP3956035A1 (en) 2022-02-23
KR20220004089A (ko) 2022-01-11
JP7709384B2 (ja) 2025-07-16
EP3956035A4 (en) 2023-01-25
US20220175779A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
IL287115A (en) Anticancer compounds containing egfr mutations resistant to tyrosine kinase inhibitors
IL288522A (en) Inhibitor of egfr for cancer treatment
CY1123592T1 (el) Αναστολεας κινασης aurora a
SG11202106435QA (en) Treating gastric cancer using ttfields combined with xelox or folfox
ZA202108775B (en) New egfr inhibitors
PL3656769T3 (pl) Związek arylo-fosforowo-tlenowy jako inhibitor kinazy egfr
IL279258B (en) tyrosine kinase inhibitors
EP3399968B8 (en) Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
EP3648753A4 (en) SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF EGFR TYROSINE KINASE
PT3533796T (pt) Composto de amino pirazolopirimidina utilizado como inibidor do recetor do fator neurotrófico tirosina quinase
SG11201607706SA (en) Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
EP3246328A4 (en) Quinazoline heterocyclic compound as egfr kinase inhibitor, and preparation and application thereof
IL286727A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
IL274037A (en) A pyrimidine compound as a JAK kinase inhibitor
GB201919219D0 (en) Cancer biomarkers
IL265829B (en) Quinoxaline compounds as type iii receptor tyrosine kinase inhibitors
EP3986411A4 (en) SMALL MOLECULAR INHIBITORS OF SRC TYROSINE KINASE
IL284856A (en) DBAIT molecule in combination with a kinase inhibitor for cancer treatment
GB202011996D0 (en) Antagonist compounds
IL290798A (en) Prodrugs of the tyrosine kinase inhibitor for treating cancer
MX2015010854A (es) Combinaciones de un compuesto inhibidor de mek con un compuesto inhibidor de her3/egfr y metodos de uso.
IL269144A (en) Pyrrolotriazine derivatives as kinase inhibitors
GB201909468D0 (en) Compounds for treating cancer
GB201913957D0 (en) Cancer
GB201807845D0 (en) Kinase Inhibitors